Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (PLRX)
NASDAQ:PLRX
PLRX Stock Chart & Stats
$1.49
-$0.35(-2.64%)
At close: 4:00 PM EST
$1.49
-$0.35(-2.64%)
Day’s Range― - ―
52-Week Range$1.10 - $15.27
Previous CloseN/A
Volume34.91K
Average Volume (3M)581.13K
Market Cap
$98.83M
Enterprise Value-$131.29M
Total Cash (Recent Filing)$241.80M
Total Debt (Recent Filing)$59.86M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 03, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding61,388,153
10 Day Avg. Volume902,150
30 Day Avg. Volume581,135
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.62
Price to Sales (P/S)0.00
P/FCF Ratio-5.00
Enterprise Value/Market Cap-1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit146.69
Enterprise Value/Ebitda0.78
Forecast
1Y Price Target
$3.00Price Target Upside101.34% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Antitumor ActivityThe study reported interim results from the first three cohorts, demonstrating an antitumor activity of PLN-101095+pembrolizumab combination therapy, with three partial responses observed in cohort three.
Clinical TrialsPatient enrollment of the open-label Phase I study for PLN-101095 (αvβ8 & αvβ1 dual inhibitor) has been completed.
Future Data ReleasePliant anticipated additional data read-out from the Phase I trial.
Bears Say
Development PipelineMaintain Hold on a limited development pipeline and lack of upside.
Discontinued ProgramsThe recent discontinuation of the phase 2b BEACON-IPF study is seen as a fundamental setback for bexotegrast.
Market PerformanceAnalyst believes PLRX will remain an underperformer relative to its peers in the coverage universe.
Pliant Therapeutics News
PLRX FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $1.10 and its highest was $15.27 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is $98.83M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 89 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.524 by $0.094.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 61,388,153 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.524. Following the earnings report the stock price went up 4.575%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in PLRX
Pliant Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.00 (101.34% Upside)
$3.00 (101.34% Upside)
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.21%
12-Months-Change
Fundamentals
Return on Equity
-64.27%
Trailing 12-Months
Asset Growth
-38.02%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics (PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrotic diseases. The company operates in the biotechnology and pharmaceuticals sector, leveraging its proprietary platform to identify and advance small molecule therapeutics targeting key pathways in fibrosis, a process implicated in a wide array of serious diseases. Pliant's core products are centered on treating diseases like idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
PLRX Stock 12 Month Forecast
Average Price Target
$3.00
▲(101.34% Upside)
Technical Analysis
Ownership Overview
3.65% Insiders
5.99% Mutual Funds
34.03% Other Institutional Investors
51.28% Public Companies and
Individual Investors